NVS
Novartis AG
NYSE · Healthcare · Drug Manufacturers - General · CH
$159.87
−1.97%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
17.1x
EV/EBITDA
15.5x
Market Cap
$303.87B
MomentumView details →
1D Return
−1.97%
YTD Return
+16.10%
RSI (14)
55.3
ValuationView details →
P/E (Fwd)
17.1x
EV/EBITDA
15.5x
Market Cap
$303.87B
RSI (14)
55.3
MomentumView details →
1D Return
−1.97%
YTD Return
+16.10%
SummaryUpdated Jun 1, 2026
Novartis AG (NYSE:NVS) is a Swiss multinational pharmaceutical corporation founded in 1996 through the merger of Ciba-Geigy and Sandoz. Headquartered in Basel, Switzerland, Novartis has evolved into one of the world's largest pharmaceutical companies, focusing on innovative prescription medicines across multiple therapeutic areas. The company completed a significant strategic transformation in 2023 by spinning off its generics division Sandoz, allowing it to focus entirely on developing and commercializing breakthrough treatments for serious diseases.
Similar companies
Latest newsMore news →
Novartis plans to cease production at its Kleinhüningen site in Basel, potentially eliminating about 130 jobs, subject to information and consultation procedures.2d agoSouth Korea's Alteogen signed a deal with Swiss drugmaker Novartis worth up to $3.22 billion, granting Novartis access to Alteogen's technology for making injectable versions of intravenous drugs.2d ago